Kansai Rosai Hospital Cardiovascular Center, Amagasaki, Japan.
Department of Diabetes Care Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
J Endovasc Ther. 2024 Apr;31(2):263-273. doi: 10.1177/15266028221120519. Epub 2022 Sep 1.
This study investigated the incidence of acute thrombotic occlusion (ATO) and its predictors after contemporary femoropopliteal (FP) endovascular therapy (EVT) for peripheral artery disease.
We retrospectively examined 763 limbs (chronic limb-threatening ischemia [CLTI]: 44%, involving popliteal lesion: 44%) in 644 patients (mean age: 75±9 years, male: 71%, hemodialysis: 34%) who successfully underwent EVT with contemporary FP devices (drug-coated stent: n=220, stent graft: n=158, drug-eluting stent: n=150, drug-coated balloon [DCB]: n=235) from June 2012 to July 2020. The outcome measure was ATO defined as acute onset of claudication and/or signs of CLTI in combination with angiographic evidence of occlusive thrombus formation within the treated segment. Cox proportional hazards regression models were used to identify baseline characteristics associated with the incidence of ATO after EVT treated with scaffold. To determine the impact of ATO occurrence and creatine phosphokinase (CPK) elevation on the subsequent composite outcome of mortality or major amputation, we developed the Cox model in which the trichotomous variable (free from ATO, ATO without CPK elevation, and ATO with CPK elevation) was a time-dependent covariate.
The 24-month incidence of ATO in the overall population was 4.3%±0.8% (DCB: 1.0%±0.7% vs scaffold: 5.8%±1.1%, p<0.01). Hemodialysis (hazard ratio [HR]: 2.63, p=0.02) and involving popliteal lesion (HR: 8.22, p<0.01) were independently associated with an increased risk of ATO in patients treated with scaffold. Both ATO without CPK elevation and ATO with CPK elevation were significantly associated with a composite outcome of mortality or major amputation comparing free from ATO, with an HR of 2.39 and 9.87, respectively (p=0.02 and p<0.01).
We found a substantial incidence of ATO after contemporary FP-EVT, particularly with scaffold. Hemodialysis and involving popliteal lesion were significantly associated with ATO risk in patients treated with scaffold. The occurrence of ATO, particularly with CPK elevation, was associated with an increased risk of a subsequent composite outcome of or major . The scaffold was safely used in patients without those risk factors of ATO, but a non-scaffolding strategy should be considered for patients with more risk factors.
The scaffold was safely used in patients without hemodialysis and involving popliteal lesion, but a non-scaffolding strategy should be considered for patients with those risk factors. The occurrence of ATO, particulary with CPK elevation, was of high risk of mortality or amputation.
本研究旨在探讨当代股腘动脉腔内治疗(EVT)后急性血栓闭塞(ATO)的发生率及其预测因素。
我们回顾性分析了 644 例患者(75±9 岁,男性占 71%,血液透析占 34%)763 条肢体(慢性肢体威胁性缺血[CLTI]:44%,累及腘动脉病变:44%)的临床资料。这些患者均成功接受了当代股腘动脉 EVT 治疗,采用的设备包括药物涂层支架(n=220)、支架移植物(n=158)、药物洗脱支架(n=150)和药物涂层球囊(DCB,n=235)。研究时间为 2012 年 6 月至 2020 年 7 月。ATO 的定义为治疗段出现急性跛行和/或 CLTI 症状,并结合血管造影显示闭塞性血栓形成的证据。采用 Cox 比例风险回归模型来识别与支架治疗后 ATO 发生率相关的基线特征。为了确定 ATO 发生和肌酸磷酸激酶(CPK)升高对随后的死亡率或主要截肢复合结局的影响,我们开发了 Cox 模型,其中三分类变量(无 ATO、无 CPK 升高的 ATO 和 CPK 升高的 ATO)是时间依赖性协变量。
总体人群中 24 个月的 ATO 发生率为 4.3%±0.8%(DCB:1.0%±0.7% vs 支架:5.8%±1.1%,p<0.01)。血液透析(HR:2.63,p=0.02)和累及腘动脉病变(HR:8.22,p<0.01)是支架治疗患者 ATO 风险增加的独立危险因素。与无 ATO 相比,无 CPK 升高的 ATO 和 CPK 升高的 ATO 与死亡率或主要截肢的复合结局显著相关,HR 分别为 2.39 和 9.87(p=0.02 和 p<0.01)。
我们发现当代股腘动脉 EVT 后 ATO 的发生率较高,尤其是支架治疗后。血液透析和累及腘动脉病变与支架治疗患者的 ATO 风险显著相关。ATO 的发生,特别是伴有 CPK 升高,与死亡率或主要截肢的复合结局的风险增加相关。在没有这些 ATO 风险因素的患者中,支架是安全的,但对于具有更多风险因素的患者,应考虑非支架策略。
在没有血液透析和累及腘动脉病变的患者中,支架是安全的,但对于具有这些风险因素的患者,应考虑非支架策略。ATO 的发生,特别是伴有 CPK 升高,与死亡率或截肢的风险较高有关。